| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Michael J. McElhaugh | Interim President & CEO, Director | $5.44M | -$78.1K | -1.41% | Feb 14, 2025 |
| Michael J. Sofia | Chief Scientific Officer | $3.82M | Feb 1, 2024 | ||
| William H. Collier | President and CEO, Director | $1.1M | Feb 1, 2023 | ||
| David C. Hastings | Chief Financial Officer | $820K | -$72.8K | -8.16% | Feb 14, 2025 |
| Karen Sims | Chief Medical Officer | $510K | -$63.5K | -11.1% | Feb 14, 2025 |
| J. Christopher Naftzger | General Counsel and CCO | $461K | -$37.2K | -7.46% | Feb 14, 2025 |
| Elizabeth Howard | EVP, GC, Compliance | $438K | Feb 1, 2023 | ||
| Keith Manchester | Director | $170K | -$32.6K | -16.1% | Aug 14, 2024 |
| Richard C. Henriques Jr | Director | May 23, 2024 | |||
| Melissa Rewolinski | Director | May 23, 2024 | |||
| James R. Meyers | Director | May 23, 2024 | |||
| Daniel D. Burgess | Director | May 23, 2024 | |||
| Roivant Sciences Ltd. | 10%+ Owner | Oct 18, 2021 | |||
| Andrew Cheng | Director | Jun 3, 2021 | |||
| Frank Torti | Director | May 23, 2024 | |||
| Tram Tran | Director | May 25, 2022 | |||
| Gaston Picchio | Chief Development Officer | Jan 20, 2022 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|